Kinter LB[au] - Search Results

Year	Number of Results
1973	1
1976	1
1979	1
1980	1
1981	1
1982	6
1983	1
1985	3
1986	6
1987	5
1988	10
1989	9
1990	3
1991	5
1992	2
1993	5
1994	3
1999	1
2002	1
2003	1
2004	2
2005	1
2009	1
2010	3
2011	2
2012	3
2013	2
2014	1
2015	3
2016	1
2017	2
2021	1
2022	1

1

A Brief History of Use of Animals in Biomedical Research and Perspective on Non-Animal Alternatives.

Kinter LB, DeHaven R, Johnson DK, DeGeorge JJ. Kinter LB, et al. ILAR J. 2021 Jun 25:ilab020. doi: 10.1093/ilar/ilab020. Online ahead of print. ILAR J. 2021. PMID: 34181728

2

Safety pharmacology and risk assessment.

Kinter LB, Valentin JP. Kinter LB, et al. Fundam Clin Pharmacol. 2002 Jun;16(3):175-82. doi: 10.1046/j.1472-8206.2002.00104.x. Fundam Clin Pharmacol. 2002. PMID: 12165065 Review.

3

A defense of 'risk-benefit' terminology.

Kinter LB, Johnson DK. Kinter LB, et al. Lab Anim (NY). 2015 Oct;44(10):403-7. doi: 10.1038/laban.875. Lab Anim (NY). 2015. PMID: 26398615

4

Anomalous antidiuretic activity of antidiuretic hormone antagonists.

Kinter LB, Caltabiano S, Huffman WF. Kinter LB, et al. Biochem Pharmacol. 1993 May 5;45(9):1731-7. doi: 10.1016/0006-2952(93)90427-x. Biochem Pharmacol. 1993. PMID: 8494530 Review. No abstract available.

5

Evaluation and applications of radiotelemetry in small laboratory animals.

Kramer K, Kinter LB. Kramer K, et al. Among authors: kinter lb. Physiol Genomics. 2003 May 13;13(3):197-205. doi: 10.1152/physiolgenomics.00164.2002. Epub 2003 May 13. Physiol Genomics. 2003. PMID: 12746464 Review.

6

A Historical View and Vision into the Future of the Field of Safety Pharmacology.

Bass AS, Hombo T, Kasai C, Kinter LB, Valentin JP. Bass AS, et al. Among authors: kinter lb. Handb Exp Pharmacol. 2015;229:3-45. doi: 10.1007/978-3-662-46943-9_1. Handb Exp Pharmacol. 2015. PMID: 26091634 Review.

7

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

Bass AS, Vargas HM, Valentin JP, Kinter LB, Hammond T, Wallis R, Siegl PK, Yamamoto K. Bass AS, et al. Among authors: kinter lb. J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):7-15. doi: 10.1016/j.vascn.2011.05.006. Epub 2011 Jun 12. J Pharmacol Toxicol Methods. 2011. PMID: 21689769 Review.

8

Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices.

Bass AS, Tomaselli G, Bullingham R 3rd, Kinter LB. Bass AS, et al. Among authors: kinter lb. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):12-21. doi: 10.1016/j.vascn.2005.04.010. J Pharmacol Toxicol Methods. 2005. PMID: 15967683 Review.

9

Scientific Knowledge and Technology, Animal Experimentation, and Pharmaceutical Development.

Kinter LB, DeGeorge JJ. Kinter LB, et al. ILAR J. 2016 Dec;57(2):101-108. doi: 10.1093/ilar/ilw027. ILAR J. 2016. PMID: 28053064

10

Fit for Purpose Assessment: A New Direction for IACUCs.

Kinter LB, Johnson DK, Weichbrod RH, Prentice ED, Simmonds RC, Houghton PW, Whitney RA Jr, DeGeorge J, DeHaven WR, Kramer K, DeTolla L. Kinter LB, et al. ILAR J. 2022 May 4:ilac006. doi: 10.1093/ilar/ilac006. Online ahead of print. ILAR J. 2022. PMID: 35512294

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results